Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL

This is a single-arm, multicenter, prospective, phase II study. The primary objective is to assess the efficacy and safety of orelabrutinib in treatment-naïve patients with marginal zone lymphoma.

Trial Details

NCT ID
NCT07441993
Phase
PHASE2
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Orelabrutinib
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Wuhan, Hubei, China|30.58333,114.26667
  • Xiangyang, Hubei, China|32.0422,112.14479
  • Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

  • Age ≥18 years, regardless of gender;
  • Patients with histopathologically confirmed stage I/II marginal zone lymphoma;
  • ECOG performance status score of 0-2;
  • Major organ functions meeting the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →